UCSF’s innovative, collaborative approach to patient care, research and education spans disciplines across the life sciences, making it a world leader in scientific discovery and its translation to improving health.
Guidance for the safe management of ambulatory patients who have COVID symptoms or recent COVID illness or exposure, who are entering the ambulatory setting for care.
For patients who have not yet received tixagevimab/cilgavimab (Evusheld) but who have active Therapy Plans and are scheduled or in the work queue for scheduling (ie REF802 was placed), instructions on how to delete the existing Therapy Plan and reorder the updated Therapy Plan for 300 mg of tixagevimab and 300 mg of cilgavimab.
For patients who have already received an initial dose of tixagevimab/cilgavimab (Evusheld) and need a catch-up dose, instructions on how to edit the Therapy Plan for all of your patients who have received a low dose of tixagevimab/cilgavimab (Evusheld) before the change in dosing recommendations went into effect.